EUVIMEDEUVIMED entdecken
Crossref

Targeted therapies in pediatric cancers

Sultan Okur Acar, Deniz Kızmazoğlu, Özlem Tüfekçi Gürocak

Developments and Experiments in Health and Medicine · 30.07.2026 · 40 (3) · 301-316

DOI: 10.18614/dehm.1955635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Developments and Experiments in Health and Medicine, online erschienen am 30.07.2026. Verfasst von Sultan Okur Acar und 2 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Childhood cancers remain one of the leading causes of disease-related mortality in the pediatric population. Although multi-agent chemotherapy protocols have significantly improved survival rates, outcomes remain suboptimal in a substantial proportion of patients with high-risk, relapsed, or refractory disease. In addition, the cumulative toxicity of conventional cytotoxic agents is associated with serious long-term morbidities. Advances in genomic profiling and molecular characterization have enhanced our understanding of the biology of leukemias and solid tumors, enabling the development of more targeted therapeutic strategies with reduced systemic toxicity. In recent years, immunotherapeutic agents such as blinatumomab and inotuzumab ozogamicin, along with chimeric antigen receptor-T cell (CAR-T) cell therapy, have fundamentally transformed the treatment paradigm for relapsed and refractory acute lymphoblastic leukemia (ALL). Furthermore, targeted therapies, including tyrosine kinase inhibitors and FLT3 inhibitors, have significantly improved survival when incorporated into conventional chemotherapy regimens in both acute myeloid leukemia and high-risk ALL. In solid tumors, immune checkpoint inhibitors, targeted small molecules, and antibody-based therapies have demonstrated promising results. This review aims to summarize the current evidence on targeted therapies in pediatric leukemias, lymphomas and solid tumors, highlight ongoing clinical trials, and discuss future perspectives regarding the integration of these agents into frontline treatment strategies.

Zitieren

APA

Acar, S. O., Kızmazoğlu, D., & Gürocak, Ö. T. (2026). Targeted therapies in pediatric cancers. Developments and Experiments in Health and Medicine, 40(3), 301-316. https://doi.org/10.18614/dehm.1955635

Vancouver

Acar SO, Kızmazoğlu D, Gürocak ÖT. Targeted therapies in pediatric cancers. Developments and Experiments in Health and Medicine. 2026;40(3):301-316. doi:10.18614/dehm.1955635

BibTeX
@article{Acar2026,
  author = {Acar, Sultan Okur and Kızmazoğlu, Deniz and Gürocak, Özlem Tüfekçi},
  title = {Targeted therapies in pediatric cancers},
  journal = {Developments and Experiments in Health and Medicine},
  year = {2026},
  volume = {40},
  number = {3},
  pages = {301--316},
  doi = {10.18614/dehm.1955635}
}
Kostenlos starten →